Formatech, Inc. has announced the selection of Tracon Pharmaceuticals' TRC102 clinical product as the next Fillanthropy(TM) Program candidate. Under this program, Formatech donates the services required to aseptically fill and finish one lot of the drug candidate to support Tracon's upcoming clinical trials.
"TRC102 is a small molecule inhibitor of DNA base excision repair that shows very promising results in animal models and cancer patients when administered in conjunction with chemotherapeutic agents such as Temodar(R) and Alimta(R)," said Jeffrey Bernard, Formatech's Director of Business Development. "This compound appears to potentiate chemotherapeutic efficacy as well as prevent drug resistance. We're excited to play a role in the development of this beneficial compound."
"We are pleased to be able to work with Formatech, one of the leaders in the field of drug product formulation and manufacture," said Charles Theuer, Tracon's President and CEO. "We are deeply appreciative that their Fillanthropy Program will allow us to continue our Phase 1 study of TRC102 in combination with Temodar for advanced cancer patients, and to initiate a Phase 2 study of TRC102 in combination with Alimta for patients with lung cancer."
About the Fillanthropy Program
Each month, Formatech will select a company to donate the services required to aseptically fill and finish one lot of drug product entering human clinical trials. We consider both the product's potential therapeutic benefit and the financial need of the applicant. To apply, companies are encouraged to contact Jeffrey Bernard at 978-725-9077 x 3164 or email@example.com.